S&P 500   3,239.36 (-2.41%)
DOW   26,840.87 (-2.95%)
QQQ   261.01 (-2.20%)
AAPL   104.91 (-1.81%)
MSFT   196.95 (-1.72%)
FB   244.91 (-3.02%)
GOOGL   1,406.65 (-3.06%)
AMZN   2,880.06 (-2.53%)
NVDA   478.11 (-1.94%)
TSLA   424.00 (-4.10%)
BABA   266.73 (-2.09%)
CGC   15.57 (-4.83%)
MU   48.34 (-4.73%)
GE   6.33 (-7.99%)
AMD   75.10 (+0.23%)
T   28.51 (-1.45%)
F   6.84 (-5.39%)
ACB   6.24 (-4.44%)
GILD   63.73 (-2.03%)
NFLX   469.68 (-0.06%)
DIS   123.70 (-3.83%)
BAC   24.19 (-4.05%)
BA   155.50 (-3.50%)
S&P 500   3,239.36 (-2.41%)
DOW   26,840.87 (-2.95%)
QQQ   261.01 (-2.20%)
AAPL   104.91 (-1.81%)
MSFT   196.95 (-1.72%)
FB   244.91 (-3.02%)
GOOGL   1,406.65 (-3.06%)
AMZN   2,880.06 (-2.53%)
NVDA   478.11 (-1.94%)
TSLA   424.00 (-4.10%)
BABA   266.73 (-2.09%)
CGC   15.57 (-4.83%)
MU   48.34 (-4.73%)
GE   6.33 (-7.99%)
AMD   75.10 (+0.23%)
T   28.51 (-1.45%)
F   6.84 (-5.39%)
ACB   6.24 (-4.44%)
GILD   63.73 (-2.03%)
NFLX   469.68 (-0.06%)
DIS   123.70 (-3.83%)
BAC   24.19 (-4.05%)
BA   155.50 (-3.50%)
S&P 500   3,239.36 (-2.41%)
DOW   26,840.87 (-2.95%)
QQQ   261.01 (-2.20%)
AAPL   104.91 (-1.81%)
MSFT   196.95 (-1.72%)
FB   244.91 (-3.02%)
GOOGL   1,406.65 (-3.06%)
AMZN   2,880.06 (-2.53%)
NVDA   478.11 (-1.94%)
TSLA   424.00 (-4.10%)
BABA   266.73 (-2.09%)
CGC   15.57 (-4.83%)
MU   48.34 (-4.73%)
GE   6.33 (-7.99%)
AMD   75.10 (+0.23%)
T   28.51 (-1.45%)
F   6.84 (-5.39%)
ACB   6.24 (-4.44%)
GILD   63.73 (-2.03%)
NFLX   469.68 (-0.06%)
DIS   123.70 (-3.83%)
BAC   24.19 (-4.05%)
BA   155.50 (-3.50%)
S&P 500   3,239.36 (-2.41%)
DOW   26,840.87 (-2.95%)
QQQ   261.01 (-2.20%)
AAPL   104.91 (-1.81%)
MSFT   196.95 (-1.72%)
FB   244.91 (-3.02%)
GOOGL   1,406.65 (-3.06%)
AMZN   2,880.06 (-2.53%)
NVDA   478.11 (-1.94%)
TSLA   424.00 (-4.10%)
BABA   266.73 (-2.09%)
CGC   15.57 (-4.83%)
MU   48.34 (-4.73%)
GE   6.33 (-7.99%)
AMD   75.10 (+0.23%)
T   28.51 (-1.45%)
F   6.84 (-5.39%)
ACB   6.24 (-4.44%)
GILD   63.73 (-2.03%)
NFLX   469.68 (-0.06%)
DIS   123.70 (-3.83%)
BAC   24.19 (-4.05%)
BA   155.50 (-3.50%)
Log in
OTCMKTS:ISCO

International Stem Cell Stock Forecast, Price & News

$0.55
-0.07 (-11.29 %)
(As of 09/18/2020 08:10 PM ET)
Add
Compare
Today's Range
$0.55
Now: $0.55
$0.58
50-Day Range
$0.56
MA: $0.66
$0.80
52-Week Range
$0.27
Now: $0.55
$1.20
Volume3,126 shs
Average Volume5,546 shs
Market Capitalization$4.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ISCO
CUSIP460378102
Phone760-940-6383

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.47 million
Book Value($0.38) per share

Profitability

Net Income$-4,260,000.00

Miscellaneous

Employees42
Market Cap$4.15 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$0.55
-0.07 (-11.29 %)
(As of 09/18/2020 08:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISCO News and Ratings via Email

Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions

How has International Stem Cell's stock price been impacted by Coronavirus?

International Stem Cell's stock was trading at $0.5850 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ISCO stock has decreased by 6.0% and is now trading at $0.55.
View which stocks have been most impacted by COVID-19
.

When is International Stem Cell's next earnings date?

International Stem Cell is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for International Stem Cell
.

How were International Stem Cell's earnings last quarter?

International Stem Cell Corp (OTCMKTS:ISCO) posted its quarterly earnings data on Wednesday, August, 12th. The biotechnology company reported ($0.14) EPS for the quarter. The biotechnology company had revenue of $1.81 million for the quarter.
View International Stem Cell's earnings history
.

Who are some of International Stem Cell's key competitors?

What other stocks do shareholders of International Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other International Stem Cell investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Athersys (ATHX), Turkcell Iletisim Hizmetleri A.S. (TKC), Biocept (BIOC), Capricor Therapeutics (CAPR), Canopy Growth (CGC), Neuralstem (CUR), FuelCell Energy (FCEL) and IntelGenx Technologies (IGXT).

Who are International Stem Cell's key executives?

International Stem Cell's management team includes the following people:
  • Prof. Andrey Semechkin, Co-Chairman & CEO (Age 59)
  • Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 33)
  • Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 35)
  • Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC

What is International Stem Cell's stock symbol?

International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."

How do I buy shares of International Stem Cell?

Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is International Stem Cell's stock price today?

One share of ISCO stock can currently be purchased for approximately $0.55.

How big of a company is International Stem Cell?

International Stem Cell has a market capitalization of $4.15 million and generates $9.47 million in revenue each year. International Stem Cell employs 42 workers across the globe.

What is International Stem Cell's official website?

The official website for International Stem Cell is www.internationalstemcell.com.

How can I contact International Stem Cell?

International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.